Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Completed · Not applicable
Conditions studied: Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
In brief
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
Key facts
- Study ID
- NCT00537056
- Run by
- Stanford University
- People needed
- 17
- Starts
- 2007-10-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2017-06-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.